萊茵生物(002166.SZ):2878.5萬元競得華高生物47.5%股權
格隆匯 10 月 12日丨萊茵生物(002166.SZ)公佈,四川省國有資產經營投資管理有限責任公司(“四川國資”)、成都華高藥業有限公司(“華高藥業”)於2020年9月3日在西南聯合產權交易所公開掛牌轉讓其持有的成都華高生物製品有限公司(“華高生物”、“標的公司”)合計47.5%股權(“標的股權”)。標的股權掛牌價格為2,878.5萬元,公開掛牌時間為2020年9月3日-2020年9月29日。公司報名作為意向受讓方參與了上述股權轉讓項目的競買,並於9月25日支付了參與競買股權保證金人民幣450萬元。上述標的股權掛牌公告期結束,公司成為唯一合格意向受讓方。2020年10月12日,公司與四川國資、華高藥業簽訂了《聯合轉讓交易合同》,以人民幣2878.5萬元競得華高生物47.5%股權。
標的公司華高生物成立於2007年3月,主要從事食品添加劑(茶多酚;茶多酚棕櫚酸酯;茶黃素;綠茶酊;紅茶酊)的研發、生產和銷售,主要產品有綠茶提取物和虎杖提取物,其產品廣泛應用於天然藥品、保健品、健康食品、日用化粧品等領域。根據2019年中國海關統計數據顯示,華高生物綠茶提取物出口額位列第一,是國內綠茶及虎杖提取領域的龍頭企業。
華高生物的產品線與公司存在很高的互補性,此次股權收購目的主要是通過整合行業優勢資源,充分發揮公司和標的公司在人才、管理、產品、工藝和市場客户等方面的優勢,實現資源互補、優勢協同,進一步推動公司“大單品”發展策略的實施落地,提升公司在植物提取領域優勢品種的市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.